Medtronic has received approval from the US Food and Drug Administration (FDA) for its MiniMed 670G hybrid closed looped system for type 1 diabetes.

How well do you really know your competitors?

Access the most comprehensive Company Profiles on the market, powered by GlobalData. Save hours of research. Gain competitive edge.

Company Profile – free sample

Thank you!

Your download email will arrive shortly

Not ready to buy yet? Download a free sample

We are confident about the unique quality of our Company Profiles. However, we want you to make the most beneficial decision for your business, so we offer a free sample that you can download by submitting the below form

By GlobalData
Visit our Privacy Policy for more information about our services, how we may use, process and share your personal data, including information of your rights in respect of your personal data and how you can unsubscribe from future marketing communications. Our services are intended for corporate subscribers and you warrant that the email address submitted is your corporate email address.

MiniMed 670G is fitted with Guardian Sensor, Medtronic's newest and advanced glucose sensor. This controls the hybrid closed loop system and uses diagnostic technology for a continuous monitoring of the sensor health.

MiniMed 670G is also driven by the SmartGuard HCL algorithm, which helps deliver a variable rate of insulin 24 hours a day tailored to the needs of the patient.

"We are very encouraged by the speed in which this groundbreaking technology was approved by the FDA."

The new system is intuitive to the individual's insulin needs and the patient only requires to enter mealtime carbohydrates, accept bolus correction recommendations, and periodically calibrate the sensor.

Charitable organisation JDRF's president and CEO Derek Rapp said: "This significant milestone represents an important step forward in the management of type 1 diabetes and will improve the quality of life for those living with this chronic disease.

"We are very encouraged by the speed in which this groundbreaking technology was approved by the FDA, and we are proud of the role JDRF played in achieving this exciting breakthrough.”

The Medtronic system is currently approved to treat type 1 diabetes patients aged 14 years and above and is being evaluated to expand its usage across additional patient populations.

Image: MiniMed 670G System. Photo: courtesy of Medtronic plc.